IGXT Stock UPDATES Intelgenx Technologs (IGXT) 0.5000 09/15/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intelgenx Technologs (IGXT) 0.5000 $IGXT

IntelGenx to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Aug 21, 1:18PM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference to be held September 9, 2014 at 9:35 a.m. Eastern Time.

H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

IntelGenx Reports Q2, 2014 Results and Provides Corporate Development Update
GlobeNewswire - Thu Aug 07, 8:31AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced financial results for the three and six months ended June 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx to Host Management Call
GlobeNewswire - Fri Jul 18, 11:38AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its interim CEO, Dr. Horst G. Zerbe, will be hosting a conference call on July 23rd, 2014 at 10:00 AM Eastern Time.

IntelGenx Announces Management Changes
GlobeNewswire - Wed Jul 16, 3:52AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" announced today that the board of directors (the "Board" of IntelGenx has accepted, with immediate effect, the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer ("CEO" of IntelGenx and as a member of the Board.

IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright
GlobeNewswire - Tue Jul 01, 7:11AM CDT
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that H.C. Wainwright has initiated equity analyst coverage of IntelGenx.

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
GlobeNewswire - Tue Mar 11, 7:32AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" today announced financial results for its fiscal year ended December 31, 2013 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA" from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.

IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.

IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data

11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.

IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par" for two new products utilizing IntelGenx' proprietary oral drug delivery platforms.

IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company" (TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ghj69/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Idiopathic Pulmonary Fibrosis. - A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Sanofi-Aventis GlaxoSmithKline plc MedImmune LLC Gilead Sciences, Inc. FibroGen, Inc. Chong Kun Dang Pharmaceutical InterMune, Inc. IntelGenx Technologies Corp. Compugen Ltd. Pharmaxis Ltd. Hanall Pharmaceutical Co., Ltd. LTT Bio-Pharma Co., Ltd. Auspex Pharmaceuticals Promedior, Inc. Mondobiotech Holding AG GenKyoTex S.A. Stromedix, Inc. ImmuneRegen BioSciences, Inc. ImmuneWorks, LLC Histocell S.L. BiOrion Technologies B.V. Pacific Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/4ghj69/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 105

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 69

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 73

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 107

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 119

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 93

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Mauna Kea Technologies Advances AI Integration in Endomicroscopy

Updated Category News Views 512

Mauna Kea Technologies and its Innovative AI Patent Mauna Kea Technologies, the proud inventor of Cellvizio®, a revolutionary platform that blends probe and needle-based confocal laser endomicroscopy (p/nCLE), has taken a significant step forward in the realm of artificial intelligence in medical diagnostic procedures. Recently, the company announced the granting of a...

Continue Reading
Hot Chili Limited Secures Approval for La Verde Expansion Drilling

Updated Category News Views 168

Hot Chili Limited's Significant Progress at La Verde Hot Chili Limited (OTCQX: HHLKF) has obtained key regulatory approval to enhance the drill coverage of its La Verde copper-gold discovery. This exciting development comes as the company aims to broaden exploration activities in an area strategically important to its operations. Understanding the La Verde Project The La...

Continue Reading
Investors on High Alert as Lithium Faces Growing Demand Challenges

Updated Category News Views 261

The Lithium Debate: Rising Tensions at COP30 At the recent climate discussions, the dialogue took an unexpected turn, raising eyebrows among investors in various clean-tech sectors. For the first time in thirty years of United Nations climate negotiations, serious concerns emerged regarding the social and environmental risks associated with lithium mining, which is...

Continue Reading
Edible Garden Expands USDA Organic Herb Line in New Markets

Updated Category News Views 71

Introducing Edible Garden's Organic Product Line Edible Garden AG Incorporated has been making headlines as a leader in controlled environment agriculture (CEA). Recently, they launched their USDA Organic herb product line at Green’s Natural Foods and The Extra Supermarket, which is a significant step in their mission to provide sustainably grown and organic produce....

Continue Reading
Growth Surge: The Value of $100 Investment in Riot Platforms

Updated Category News Views 148

Understanding the Rise of Riot Platforms Investors seeking substantial growth often look to companies like Riot Platforms (NASDAQ: RIOT), which has demonstrated impressive performance over the past five years. With a remarkable annualized return of 46.95%, Riot has outpaced the market by over 34.28%. This consistent growth contributes to a current market capitalization of...

Continue Reading